Last reviewed · How we verify

estradiol plus MPA

Peking Union Medical College Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

estradiol plus MPA is a Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved.

Estradiol, an estrogen receptor alpha agonist, is used in combination with medroxyprogesterone acetate (MPA) to treat conditions such as estrogen deficiency, cardiovascular disease, and endothelial dysfunction. This combination is typically administered in a dosage of 0.625 mg of conjugated equine estrogen plus 2.5 mg of MPA.

At a glance

Generic nameestradiol plus MPA
SponsorPeking Union Medical College Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about estradiol plus MPA

What is estradiol plus MPA?

estradiol plus MPA is a Small molecule drug developed by Peking Union Medical College Hospital.

Who makes estradiol plus MPA?

estradiol plus MPA is developed and marketed by Peking Union Medical College Hospital (see full Peking Union Medical College Hospital pipeline at /company/peking-union-medical-college-hospital).

What development phase is estradiol plus MPA in?

estradiol plus MPA is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing